Is Zoetis Stock Underperforming the S&P 500?

Zoetis Inc. (ZTS), a world-leading animal health company, is trading 50.9% below its 52-week high as of September 5, 2025. Despite its substantial market capitalization of $31.9 billion, ZTS has underperformed the S&P 500, which has seen a modest 12% year-to-date gain. The company's stock has plummeted 39.5% year-to-date and 50.2% over the past 52 weeks, making it significantly less profitable than its peers.

Despite recent positive news, including a 3.9% increase following strong Q2 results, Zoetis continues to lag the broader market and its competitors, such as United Therapeutics Corporation (UTHR), which has outperformed ZTS by 21.5% over the past year. Analysts are cautiously optimistic about ZTS's future, with a moderate buy rating and a mean price target of $97.69, suggesting a 28.3% upside potential.